The Clinical Research E-News

Volume 2: ISSUE 21: December 1, 2010

Now Open:
E5508, Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Coming soon:
ECOG1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma

E2208, Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer

E3108, A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen

NSABP C-11, A Phase III Study Evaluating the Role of Preoperative Chemotherapy and Bevacizumab in Patients with Potentially Resectable Hepatic Colorectal Metastases

RTOG 0631, Phase II/III Study of Image-Guided Radiosurgery/SBRT forLocalized Spine Metastasis
**RTOG0912**, *A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib/Placebo, for the Treatment of Anaplastic Thyroid Cancer*

**RTOG 0929**, *A Randomized, Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma*

**RTOG 1008**, *A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors*

**RTOG 1014**, *A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Irradiation (PBRI) for Local Recurrence of Breast Carcinoma*

If your site is interested in participating in any of these studies please contact Rolma Gano at 215-955-7954 or Rolma.gano@jeffersonhospital.org.

**Regulatory Update:**
- E5508 new study
- C40502 update #3
- S0307 revision #7
- **E2804 addendum #10- reconsent**
- E5204 addendum #6
- PACCT-1 Update #5
- **S0518 Revision #4- reconsent**

Please contact Rolma Gano with any repository or other regulatory related questions.
CTSU Update:
Please contact Joshua Schoppe with any CTSU related issues at 215-955-0448 or Joshua.Schoppe@jeffersonhospital.org

ECOG Update:
**E2804**, *The BEST Trial: A Randomized Phase II Study of VEGF, RAF kinase and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma* will close to accrual on December 10, 2010. Patients currently on this study should be followed according to the protocol. Sample submissions should continue during the follow-up period as specified in the protocol.

If you have an ECOG related question please contact Joshua Schoppe.

NSABP Update:
The **BETH Trial** has closed to accrual nearly 5 months earlier than initially planned. The accrual for this international trial was 3200. North America contributed approximately 40% of the total accrual. Other participating regions are South America, Asia Pacific, China, Europe and Africa. The trial is a great model for international cooperation. A BETH Newsletter with more interesting details is available. Please contact Vicki Squire for a copy.

If you are participating in **NSABP B-46-I**, please check out a new posting on the Division of Industry Trials: "Frequently Asked Questions". It is an excellent tool to assist with screening and eligibility. **NSABP** has announced their next group meeting. It is scheduled for March 24-27, 2011 in Boca Raton, FL. Meeting and travel information will be sent mid-January.

If you have an NSABP related question please contact Vicki Squire at vicki.squire@jeffersonhospital.org or at 215-503-5641.
RTOG Update:

Attention all RTOG 0825 Phase III GBM study participant: An important statistical analysis is planned for this study. Please review the OPS tool and patient calendars and submit all data due by December 15th, 2010.

Registration for the RTOG Semiannual Meeting is now available at https://registrations.acr.org/rtog. The meeting will be held in San Diego, January 13-16, 2011. The meeting agenda and brochure can be found on the RTOG website at http://www.rtog.org/meeting/main.html.

Please review the attached RTOG November newsletter for additional RTOG updates.

Please contact Joshua Schoppe or Vicki Squire with any RTOG related issues.

Jefferson Oncology Group (JOG) Update:
If your site has any JOG inquiries please contact either Joshua Schoppe or Vicki Squire.

Jefferson Kimmel Cancer Center Network Homepage: http://www.kimmelcancercenter.org/jkccn/. This page contains links to the Remote Access Portal as well as the clinical trial document repository.

Upcoming Events:

JKCNN CRA Meeting, Philadelphia, PA: December 8. Please RSVP to Vicki Squire if you plan to attend the luncheon by Monday December 6th at 2pm.

RTOG Semiannual Meeting, San Diego, CA: January 13-16
NSABP Semiannual Meeting, Boca Raton, FL: March 24-27
The Clinical Research E-News Archive is now located on the Kimmel Cancer Center webpage under the JKCCN Member Area:
http://www.kimmelcancercenter.org/jkccn/e-newsletters.html

Please provide feedback and any suggestions to Joshua Schoppe at 215-955-0448 or email Joshua.schoppe@jeffersonhospital.org